1.Triaging Primary Care Patients Referred for Chest Pain to Specialist Cardiology Centres: Efficacy of an Optimised Protocol.
Francine Cl TAN ; Jonathan YAP ; John C ALLEN ; Olivia TAN ; Swee Yaw TAN ; David B MATCHAR ; Terrance Sj CHUA
Annals of the Academy of Medicine, Singapore 2018;47(2):56-62
INTRODUCTION:
Patients referred for chest pain from primary care have increased, along with demand for outpatient cardiology consultations. We evaluated 'Triage Protocol' that implements standardised diagnostic testing prior to patients' first cardiology consultation.
MATERIALS AND METHODS:
Under the 'Triage Protocol', patients referred for chest pain were pretriaged using a standardised algorithm and subsequently referred for relevant functional diagnostic cardiology tests before their initial cardiology consultation. At the initial cardiology consultation scheduled by the primary care provider, test results were reviewed. A total of 522 triage patients (mean age 55 ± 13, male 53%) were frequency-matched by age, gender and risk cohort to 289 control patients (mean age: 56 ± 11, male: 52%). Pretest risk of coronary artery disease was defined according to a Modified Duke Clinical Score (MDCS) as low (<10), intermediate (10-20) and high (>20). The primary outcome was time from referral to diagnosis (days). Secondary outcomes were total visits, discharge rate at first consultation, patient cost and adverse cardiac outcomes.
RESULTS:
The 'Triage Protocol' resulted in shorter times from referral to diagnosis (46 vs 131 days; <0.0001) and fewer total visits (2.4 vs 3.0; <0.0001). However, triage patients in low-risk groups experienced higher costs due to increased testing (S$421 vs S$357, = 0.003). Adverse cardiac event rates under the 'Triage Protocol' indicated no compromise to patient safety (triage vs control: 0.57% vs 0.35%; = 1.000).
CONCLUSION
By implementing diagnostic cardiac testing prior to patients' first specialist consultation, the 'Triage Protocol' expedited diagnosis and reduced subsequent visits across all risk groups in ambulatory chest pain patients.
Algorithms
;
Cardiology Service, Hospital
;
Chest Pain
;
therapy
;
Clinical Protocols
;
Female
;
Humans
;
Male
;
Middle Aged
;
Primary Health Care
;
Treatment Outcome
;
Triage
;
methods
4.Asia's first successful minimally invasive transapical transcatheter mitral valve-in-valve implantation.
Jia Lin SOON ; Yeow Leng CHUA ; Victor Tt CHAO ; Paul Tl CHIAM ; See Hooi EWE ; Ving Yuen SEETHO ; Chung Yin LEE ; Swee Yaw TAN ; Tian Hai KOH ; Kenny Yk SIN
Annals of the Academy of Medicine, Singapore 2013;42(2):85-87
5.Impact of aortic annular size and valve type on haemodynamics and clinical outcomes after transcatheter aortic valve implantation.
Samuel Ji Quan KOH ; Jonathan YAP ; Yilin JIANG ; Julian Cheong Kiat TAY ; Kevin Kien Hong QUAH ; Nishanth THIAGARAJAN ; Swee Yaw TAN ; Mohammed Rizwan AMANULLAH ; Soo Teik LIM ; Zameer Abdul AZIZ ; Sivaraj GOVINDASAMY ; Victor Tar Toong CHAO ; See Hooi EWE ; Kay Woon HO
Annals of the Academy of Medicine, Singapore 2022;51(10):605-618
INTRODUCTION:
Data on patients with small aortic annuli (SAA) undergoing transcatheter aortic valve implantation (TAVI) are limited. We aim to describe the impact of aortic annular size, particularly SAA and TAVI valve type on valve haemodynamics, durability and clinical outcomes.
METHOD:
All patients in National Heart Centre Singapore who underwent transfemoral TAVI for severe symptomatic native aortic stenosis from July 2012 to December 2019 were included. Outcome measures include valve haemodynamics, prosthesis-patient mismatch (PPM), structural valve degeneration (SVD) and mortality.
RESULTS:
A total of 244 patients were included. The mean Society of Thoracic Surgeons score was 6.22±6.08, with 52.5% patients with small aortic annulus (<23mm), 33.2% patients with medium aortic annulus (23-26mm) and 14.3% patients with large aortic annulus (>26mm). There were more patients with self-expanding valve (SEV) (65.2%) versus balloon-expandable valve (BEV) (34.8%). There were no significant differences in indexed aortic valve area (iAVA), mean pressure gradient (MPG), PPM, SVD or mortality across all aortic annular sizes. However, specific to the SAA group, patients with SEV had larger iAVA (SEV 1.19±0.35cm2/m2 vs BEV 0.88±0.15cm2/m2, P<0.01) and lower MPG (SEV 9.25±4.88 mmHg vs BEV 14.17±4.75 mmHg, P<0.01) at 1 year, without differences in PPM or mortality. Aortic annular size, TAVI valve type and PPM did not predict overall mortality up to 7 years. There was no significant difference in SVD between aortic annular sizes up to 5 years.
CONCLUSION
Valve haemodynamics and durability were similar across the different aortic annular sizes. In the SAA group, SEV had better haemodynamics than BEV at 1 year, but no differences in PPM or mortality. There were no significant differences in mortality between aortic annular sizes, TAVI valve types or PPM.
Humans
;
Transcatheter Aortic Valve Replacement
;
Heart Valve Prosthesis
;
Aortic Valve Stenosis/surgery*
;
Aortic Valve/surgery*
;
Prosthesis Design
;
Postoperative Complications/surgery*
;
Treatment Outcome
;
Hemodynamics
6.2017 Multimodality Appropriate Use Criteria for Noninvasive Cardiac Imaging: Expert Consensus of the Asian Society of Cardiovascular Imaging.
Kyongmin Sarah BECK ; Jeong A KIM ; Yeon Hyeon CHOE ; Sim Kui HIAN ; John HOE ; Yoo Jin HONG ; Sung Mok KIM ; Tae Hoon KIM ; Young Jin KIM ; Yun Hyeon KIM ; Sachio KURIBAYASHI ; Jongmin LEE ; Lilian LEONG ; Tae Hwan LIM ; Bin LU ; Jae Hyung PARK ; Hajime SAKUMA ; Dong Hyun YANG ; Tan Swee YAW ; Yung Liang WAN ; Zhaoqi ZHANG ; Shihua ZHAO ; Hwan Seok YONG
Korean Journal of Radiology 2017;18(6):871-880
In 2010, the Asian Society of Cardiovascular Imaging (ASCI) provided recommendations for cardiac CT and MRI, and this document reflects an update of the 2010 ASCI appropriate use criteria (AUC). In 2016, the ASCI formed a new working group for revision of AUC for noninvasive cardiac imaging. A major change that we made in this document is the rating of various noninvasive tests (exercise electrocardiogram, echocardiography, positron emission tomography, single-photon emission computed tomography, radionuclide imaging, cardiac magnetic resonance, and cardiac computed tomography/angiography), compared side by side for their applications in various clinical scenarios. Ninety-five clinical scenarios were developed from eight selected pre-existing guidelines and classified into four sections as follows: 1) detection of coronary artery disease, symptomatic or asymptomatic; 2) cardiac evaluation in various clinical scenarios; 3) use of imaging modality according to prior testing; and 4) evaluation of cardiac structure and function. The clinical scenarios were scored by a separate rating committee on a scale of 1–9 to designate appropriate use, uncertain use, or inappropriate use according to a modified Delphi method. Overall, the AUC ratings for CT were higher than those of previous guidelines. These new AUC provide guidance for clinicians choosing among available testing modalities for various cardiac diseases and are also unique, given that most previous AUC for noninvasive imaging include only one imaging technique. As cardiac imaging is multimodal in nature, we believe that these AUC will be more useful for clinical decision making.
Area Under Curve
;
Asian Continental Ancestry Group*
;
Clinical Decision-Making
;
Consensus*
;
Coronary Artery Disease
;
Echocardiography
;
Electrocardiography
;
Heart Diseases
;
Humans
;
Magnetic Resonance Imaging
;
Methods
;
Positron-Emission Tomography
;
Radionuclide Imaging
;
Tomography, Emission-Computed
7.Percutaneous transcatheter aortic valve implantation for degenerated surgical bioprostheses: the first case series in Asia with one-year follow-up.
Paul Toon-Lim CHIAM ; See-Hooi EWE ; Jia-Lin SOON ; Kay-Woon HO ; Yong-Koong SIN ; Swee-Yaw TAN ; Soo-Teik LIM ; Tian-Hai KOH ; Yeow-Leng CHUA
Singapore medical journal 2016;57(7):401-405
INTRODUCTIONPercutaneous transcatheter aortic valve implantation (TAVI) has become an established therapy for inoperable and high-surgical-risk patients with severe aortic stenosis. Although TAVI in patients with degenerated surgical aortic bioprostheses (i.e. valve-in-valve TAVI) is increasingly reported in Western studies, such data is lacking in Asian patients. We describe the initial experience of valve-in-valve TAVI in Asia.
METHODSEight patients who underwent valve-in-valve TAVI due to degenerated aortic bioprostheses were enrolled. The mechanism of bioprosthetic valve failure was stenotic, regurgitation or mixed. All procedures were performed via transfemoral arterial access, using the self-expanding CoreValve prosthesis or balloon-expandable SAPIEN XT prosthesis.
RESULTSThe mean age of the patients was 71.6 ± 13.2 years and five were male. Mean duration to surgical bioprosthesis degeneration was 10.2 ± 4.1 years. Valve-in-valve TAVI was successfully performed in all patients. CoreValve and SAPIEN XT prostheses were used in six and two patients, respectively. There were no deaths, strokes or permanent pacemaker requirement at 30 days, with one noncardiac mortality at one year. All patients experienced New York Heart Association functional class improvement. Post-procedure mean pressure gradients were 20 ± 11 mmHg and 22 ± 8 mmHg at 30 days and one year, respectively. Residual aortic regurgitation (AR) of more than mild severity occurred in one patient at 30 days. At one year, only one patient had mild residual AR.
CONCLUSIONIn our experience of valve-in-valve TAVI, procedural success was achieved in all patients without adverse events at 30 days. Good clinical and haemodynamic outcomes were sustained at one year.
Aged ; Aged, 80 and over ; Aortic Valve ; surgery ; Aortic Valve Insufficiency ; surgery ; Aortic Valve Stenosis ; surgery ; Arteries ; Bioprosthesis ; Cardiac Catheterization ; methods ; Female ; Fluoroscopy ; Follow-Up Studies ; Heart Valve Prosthesis ; Heart Valve Prosthesis Implantation ; Hemodynamics ; Humans ; Male ; Middle Aged ; Pacemaker, Artificial ; Prosthesis Failure ; Severity of Illness Index ; Transcatheter Aortic Valve Replacement